Small Trial Suggests DMT Can Improve Symptoms of Depression

April 7, 2023 · Ganjapreneur

Woman patient having consultation with doctor (gynecologist or psychiatrist) and examining health in medical gynecological clinic or hospital mental health service center

A trial conducted by biotechnology company Small Pharma found that the psychedelic DMT could improve symptoms of depression when used in conjunction with therapy. In the study, which used intravenous DMT dosing, 14 participants out of 34 were in remission from depression within three months and nine remained in remission up to six months. 

The study, which utilized a proprietary synthetic formulation of DMT known as SPL026, has not been peer-reviewed. 

In a press release, Dr. Carol Routledge, chief medical and scientific officer at Small Pharma, said the team is “increasingly encouraged by the treatment potential” of the drug. 

The first part of the study involved 34 patients being given the treatment during a two-and-a-half-hour clinical session with a therapist and a therapy session followed which helped participants process their experience. The second part of the study followed participants for another three months after being administered the drug, and then six more months after the study had come to an end in an assessment of its durability. 

In a joint statement, Robin Carhart-Harris PhD, director of the psychedelics division at the Weill Institute for Neurosciences at the University of California San Francisco, and Ralph Metzner distinguished professor of Neurology, Psychiatry and Behavioral Sciences, said the study’s results suggest that the drug “can elicit a fast-acting antidepressant response that appears to be enduring in several cases.”

“Recent neuroimaging and preclinical findings imply a regenerative action with DMT and other related serotonergic agonists,” Carhart-Harris and Metzner said in the statement. (Full Story)

In categories:Psychedelics Research
Next Post

Study: 1 in 10 Military Veterans Have Used Cannabis Over Past Year

A study published last month by researchers at the University of North Texas Health Science Center and College of Applied Health Sciences, University of Illinois at Urbana-Champaign found one in 10 military veterans reported using cannabis over the past year.   The study was published…
Previous Post

My Dad Was Timothy Leary, 60s Drug Icon

What would you do if Nixon called your father the “the most dangerous man in America”? Tough question – but it’s one of many that stalked Zach Leary, now 49, as he grew up in the shadow of his dad,…
Random Post

Alabama Medical Marijuana Licenses Start Going out Monday

Commission expects more lawsuits to be filed after the initial round. Alabama authorities are poised to begin doling out medical marijuana business permits as soon as Monday. Although it’s uncertain just how many licenses the state’s Medical Cannabis Commission will award next…
Random Post

Feds Release Documents Calling for Moving Cannabis to Schedule III

Officials with the U.S. Department of Health and Human Services (HHS) last week quietly released hundreds of pages of documents detailing the agency’s recommendation that cannabis be moved from Schedule I to Schedule III under the Controlled Substances Act (CSA).…
Random Post

Bipartisan Lawmakers Applaud FDA For Publishing Psychedelics Research Guidance, As They Requested In New Congressional Bill

Bipartisan congressional lawmakers are applauding the Food and Drug Administration (FDA) for releasing first-ever draft guidance on psychedelics research—a development that they had requested through a new bill just days before the agency took the step. Reps. Dan Crenshaw (R-TX), Mariannette…
Random Post

New Hampshire Senate President Says Chamber Unlikely to Approve Cannabis Legalization Bill

In an interview with the Conway Daily Sun on Thursday, New Hampshire Senate President Jeb Bradley (R) predicted the chamber would not pass the cannabis legalization law approved by the House last week. The House has passed an adult-use cannabis legalization bill three times,…